Results 191 to 200 of about 350,037 (355)
Tissue Resident Memory Cells: Friend or Foe?
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude +2 more
wiley +1 more source
Diagnostic potential of WNT signaling gene methylation in pulmonary tuberculosis. [PDF]
Wang H +7 more
europepmc +1 more source
Challenge Specific Modulation of Responses to Adjuvant‐Induced Innate Immune Memory
We utilised a commercially available adjuvant formulation to study the induction, maintenance, and consequences of innate immune memory. Using functional assays on bone marrow‐derived innate cells, extensive transcriptomic analysis of haematopoietic progenitors, and challenge models of spirochetal infection, nonspecific inflammation, and model antigen ...
Samuel T. Pasco +24 more
wiley +1 more source
Pulmonary tuberculosis in diabetes: Exploring the intersection and impact on mental health. [PDF]
Verma AK +5 more
europepmc +1 more source
RNA‐seq of lungs and livers from Mycobacterium tuberculosis‐infected mice with distinct disease outcomes revealed organ‐specific responses driven by differences in immune activity and bacterial burden. Meta‐analysis identified orthologous genes shared with human latent TB and mouse liver, with Creb3l1, Myo7b, Cyyr1 and Cbs differentially expressed and ...
Felipe T. Lima +9 more
wiley +1 more source
Effect of Isoniazid Resistance on Treatment Outcome Among People With Pulmonary Tuberculosis in Korea. [PDF]
Lee JM +20 more
europepmc +1 more source
Research progress on lung cancer complicated with pulmonary tuberculosis: a narrative review
Zejun Zhou +4 more
openalex +1 more source
Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick +13 more
wiley +1 more source

